<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Barrett's surveillance for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> is recommended, but few studies have documented the benefit of endoscopic surveillance for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVES: Using a retrospective study design, we aim to demonstrate the impact of a Barrett's surveillance program on the stage of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and identify factors for progression of <z:mpath ids='MPATH_160'>metaplasia</z:mpath> to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>SUBJECTS: The Institutional Review Board at Veterans Affairs Connecticut Healthcare approved the study </plain></SENT>
<SENT sid="3" pm="."><plain>We report a retrospective review of a prospectively followed Barrett's cohort in a surveillance program and compared their outcome with patients with a new diagnosis of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, identified at the same center between 1999 and 2005 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: There were 248 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> entered into a surveillance program from 1999 to 2005 </plain></SENT>
<SENT sid="5" pm="."><plain>During the surveillance period of 987 patient-years, 5 (0.5% patient-year) patients developed esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>During the same period, 46 patients were diagnosed with new-<z:hpo ids='HP_0003674'>onset</z:hpo> esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> outside of our surveillance program </plain></SENT>
<SENT sid="7" pm="."><plain>Only 5% of these patients had a history of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>There were 248 patients who underwent a mean number of 2.7+/-1.7 upper endoscopic procedures, with 26 (10%) patients developing <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with nonsurveillance, more patients had early stage of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the surveillance group (P &lt;.001) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 5 patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosed from <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> surveillance endoscopy were alive, compared with 20 of 46 (43%) patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosed outside of the surveillance program </plain></SENT>
<SENT sid="11" pm="."><plain>The length of Barrett's segment &gt;3 cm was found to be associated with development of <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, P=.004 (odds ratio 1.2; 95% confidence interval, 1.07-1.34) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> undergoing endoscopic surveillance benefit from early-stage <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="13" pm="."><plain>Progression to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is low, but long-segment and high-grade <z:mpath ids='MPATH_589'>dysplasias</z:mpath> have an increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>A significant number of patients with newly diagnosed esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> do not complain of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> and are therefore not investigated for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> nor entered into surveillance </plain></SENT>
<SENT sid="15" pm="."><plain>Patients and physicians can use this information in making a decision about surveillance </plain></SENT>
</text></document>